SlideShare ist ein Scribd-Unternehmen logo
1 von 32
Why to know statisticsWhy to know statistics
 To understand dataTo understand data
ExampleExample
 One of your colleague is an oncologyOne of your colleague is an oncology
surgeonsurgeon
 60% of his cases died60% of his cases died
 Does this mean that he is a looser!!Does this mean that he is a looser!!
 We should ask what are the resultsWe should ask what are the results
of his colleagues inof his colleagues in similarsimilar patientspatients
 How many patients he operatedHow many patients he operated
upon e.g 2/3!!!!upon e.g 2/3!!!!
 To summarize dataTo summarize data
ExampleExample
 Diastolic Blood pressureDiastolic Blood pressure
 80,70,65,90,74,80,60,90,60,75,80,980,70,65,90,74,80,60,90,60,75,80,9
0,100,100,100,950,100,100,100,95
 AgeAge
 24,30,26,40,28,21,26,31,32,36,27,424,30,26,40,28,21,26,31,32,36,27,4
5,62,58,52,50,605,62,58,52,50,60
Vital for researchVital for research
 Without the use of statistics it wouldWithout the use of statistics it would
be very difficult to make decisionsbe very difficult to make decisions
based on the data collected from abased on the data collected from a
research projectresearch project
Statistical steps in researchStatistical steps in research
 Collect dataCollect data
 Organise dataOrganise data
 Analyse dataAnalyse data
 Interpret the dataInterpret the data
 Present the dataPresent the data
How to read the resultsHow to read the results
 An understanding of basic statisticsAn understanding of basic statistics
will provide you with thewill provide you with the
fundamental skills necessary to readfundamental skills necessary to read
and evaluate results section inand evaluate results section in
published paperspublished papers
Are groups comparableAre groups comparable!!!!!!
 the baseline characteristics of thethe baseline characteristics of the
groups being studied should begroups being studied should be
comparablecomparable
 If not, they should be adjusted forIf not, they should be adjusted for
differencesdifferences
statistical testsstatistical tests
 Are they frequently used tests!!Are they frequently used tests!!
 If not, why!!If not, why!!
 Are the data analysed accordingAre the data analysed according
to the original protocol?to the original protocol?
 Was follow- up complete?Was follow- up complete?
Patients lost to follow-upPatients lost to follow-up………………loss ofloss of
subjects biassubjects bias
> 10% - 15 %> 10% - 15 % ……………………………………..invalid..invalid
resultsresults
P valueP value
 A P value of <0.05 means that thisA P value of <0.05 means that this
result would have arisen by chanceresult would have arisen by chance
on less than one occasion in 20on less than one occasion in 20
Standardization of measures of outcomeStandardization of measures of outcome::
Odds and odds ratioOdds and odds ratio
The odds is the number of patients who fulfilThe odds is the number of patients who fulfil
the criteria for a given endpoint divided bythe criteria for a given endpoint divided by
the number of patients who do not.the number of patients who do not.
For exampleFor example
the odds of diarrhoea during treatment with anthe odds of diarrhoea during treatment with an
antibiotic in a group of 10 patients may be 4antibiotic in a group of 10 patients may be 4
to 6 (4 with diarrhoea divided by 6 without,to 6 (4 with diarrhoea divided by 6 without,
0.66);0.66);
in a control group the odds may be 1 to 9in a control group the odds may be 1 to 9
(0.11). The odds ratio of treatment to control(0.11). The odds ratio of treatment to control
group would be 6 (0.66÷0.11).group would be 6 (0.66÷0.11).
Risk and relative riskRisk and relative risk
The risk is the number of patients whoThe risk is the number of patients who
fulfil the criteria for a given end pointfulfil the criteria for a given end point
divided by the total number of patients.divided by the total number of patients.
For exampleFor example,,
the risk of diarrhoea during treatmentthe risk of diarrhoea during treatment
with an antibiotic in a group of 10with an antibiotic in a group of 10
patients may be 4 to 10; in the controlpatients may be 4 to 10; in the control
group the risks may be 1 to 10. Thegroup the risks may be 1 to 10. The
relative risk of treatment to controlrelative risk of treatment to control
group would be 4 (0.4÷0.1).group would be 4 (0.4÷0.1).
C.IC.I
 The confidence interval around aThe confidence interval around a
result in a clinical trial indicates theresult in a clinical trial indicates the
limits within which the "real"limits within which the "real"
difference between the treatments isdifference between the treatments is
likely to lie,likely to lie,
 hence the strength of the inferencehence the strength of the inference
that can be drawn from the resultthat can be drawn from the result
Example:Example:
95 %95 % CI for RRR 25 % :CI for RRR 25 % :
 sample size 100sample size 100………………………….= -- 38 % to 59.= -- 38 % to 59
%%
 Sample size 1000Sample size 1000…………………….= 9 % to 41 %.= 9 % to 41 %
The larger the sample size , the narrower andThe larger the sample size , the narrower and
more precise the CI , and the greater ourmore precise the CI , and the greater our
confidence that the true RRR is closer toconfidence that the true RRR is closer to
what we have observedwhat we have observed..
OR = 0.34, 95% CI 0.23 - 0.52
• Odds Ratio < 1  decreased risk
• Confidence Interval does not cross 1  statistically significant
 A statistically significant result mayA statistically significant result may
not be clinically significant.not be clinically significant.
 The results of intervention trialsThe results of intervention trials
should be expressed in terms of theshould be expressed in terms of the
likely benefit an individual couldlikely benefit an individual could
expect (for example, the absoluteexpect (for example, the absolute
risk reduction)risk reduction)
How large was the treatmentHow large was the treatment
effecteffect??
Treatment effectTreatment effect………………………….. Adverse.. Adverse
outcomeoutcome
e.g.;e.g.;
Risk of outcome without therapyRisk of outcome without therapy
( baseline risk )( baseline risk ) XX ( = 20 % or 0.20 )( = 20 % or 0.20 )
Risk of outcome with therapyRisk of outcome with therapy YY ( =( =
15% 0r 0.15)15% 0r 0.15)
 Absolute risk reduction= X -- YAbsolute risk reduction= X -- Y
0.20-0.15= 0.050.20-0.15= 0.05
 Relative risk ( RR )= Y / X = 0.15 /0.20 =Relative risk ( RR )= Y / X = 0.15 /0.20 =
0.750.75
 Relative risk reduction ( RRR ) =Relative risk reduction ( RRR ) =
{ X -- Y/ X } x 100 % = 0.05 / 0.2 x{ X -- Y/ X } x 100 % = 0.05 / 0.2 x
100%= 25 % i.e :100%= 25 % i.e :
therapy reduced the risk of the outcome by 25therapy reduced the risk of the outcome by 25
% relative to that occurring among the% relative to that occurring among the
controlscontrols
the greater the RRR, the morethe greater the RRR, the more
effective the therapy.effective the therapy.
Example: M.IExample: M.I
 patients receiving medical treatmentpatients receiving medical treatment
have a chance of 404/1324=0.305 orhave a chance of 404/1324=0.305 or
30.5% of being dead at 10 years.30.5% of being dead at 10 years.
 Let us call this riskLet us call this risk xx. Patients. Patients
randomised to coronary arteryrandomised to coronary artery
bypass grafting have a chance ofbypass grafting have a chance of
350/1325=0.264 or 26.4% of being350/1325=0.264 or 26.4% of being
dead at 10 years. Let us call this riskdead at 10 years. Let us call this risk
yy..
RRRR
 The relative risk of deathThe relative risk of death——
 that is, the risk in surgically treatedthat is, the risk in surgically treated
patients compared with medicallypatients compared with medically
treated controlstreated controls——isis
 y/xy/x or 0.264/0.305=0.87 (87%).or 0.264/0.305=0.87 (87%).
RRRRRR
 The relative risk reductionThe relative risk reduction——that is,that is,
the amount by which the risk ofthe amount by which the risk of
death is reduced by the surgerydeath is reduced by the surgery——isis
100%-87% (1-100%-87% (1-yy//xx)=13%.)=13%.
ARRARR
 The absolute risk reduction (or riskThe absolute risk reduction (or risk
difference)difference)——that is, the absolutethat is, the absolute
amount by which surgical treatmentamount by which surgical treatment
reduces the risk of death at 10 yearsreduces the risk of death at 10 years
——is 30.5%-26.4%=4.1% (0.041).is 30.5%-26.4%=4.1% (0.041).
NNTNNT
 The number needed to treatThe number needed to treat——howhow
many patients need coronary arterymany patients need coronary artery
bypass grafting in order to prevent,bypass grafting in order to prevent,
on average, one death after 10 yearson average, one death after 10 years
——is the reciprocal of the absoluteis the reciprocal of the absolute
risk reduction: 1/ARR=1/0.041=24.risk reduction: 1/ARR=1/0.041=24.
ConclusionConclusion
 to be able to effectively conductto be able to effectively conduct
researchresearch
 to be able to read and evaluateto be able to read and evaluate
journal articlesjournal articles
 to further develop critical thinkingto further develop critical thinking
and analytic skillsand analytic skills
 to know when you need to hireto know when you need to hire
outside statistical helpoutside statistical help

Weitere ähnliche Inhalte

Was ist angesagt?

Introduction to medical statistics
Introduction to medical statistics Introduction to medical statistics
Introduction to medical statistics Mohamed Alhelaly
 
Basics of medical statistics
Basics of medical statisticsBasics of medical statistics
Basics of medical statisticsRamachandra Barik
 
Common measures of association in medical research (UPDATED) 2013
Common measures of association in medical research (UPDATED) 2013Common measures of association in medical research (UPDATED) 2013
Common measures of association in medical research (UPDATED) 2013Pat Barlow
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Tarekk Alazabee
 
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...Dr. Aryan (Anish Dhakal)
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Dr. Aryan (Anish Dhakal)
 
Dr Vivek Baliga - The Basics Of Medical Statistics
Dr Vivek Baliga - The Basics Of Medical StatisticsDr Vivek Baliga - The Basics Of Medical Statistics
Dr Vivek Baliga - The Basics Of Medical StatisticsDr Vivek Baliga
 
ODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONKanhu Charan
 

Was ist angesagt? (20)

Introduction to medical statistics
Introduction to medical statistics Introduction to medical statistics
Introduction to medical statistics
 
Z test
Z testZ test
Z test
 
Basics of medical statistics
Basics of medical statisticsBasics of medical statistics
Basics of medical statistics
 
NNT: Number Needed to Treat
NNT: Number Needed to TreatNNT: Number Needed to Treat
NNT: Number Needed to Treat
 
Risk factors explained_v01
Risk factors explained_v01Risk factors explained_v01
Risk factors explained_v01
 
Common measures of association in medical research (UPDATED) 2013
Common measures of association in medical research (UPDATED) 2013Common measures of association in medical research (UPDATED) 2013
Common measures of association in medical research (UPDATED) 2013
 
PMED Transition Workshop - Dynamic Treatment Regimes via Reward Ignorant Mode...
PMED Transition Workshop - Dynamic Treatment Regimes via Reward Ignorant Mode...PMED Transition Workshop - Dynamic Treatment Regimes via Reward Ignorant Mode...
PMED Transition Workshop - Dynamic Treatment Regimes via Reward Ignorant Mode...
 
Hypothesis - Biostatistics
Hypothesis - BiostatisticsHypothesis - Biostatistics
Hypothesis - Biostatistics
 
How to do the maths
How to do the mathsHow to do the maths
How to do the maths
 
The odds ratio
The odds ratioThe odds ratio
The odds ratio
 
06 Hizoh aimradial20170921 Mortality risk
06 Hizoh aimradial20170921 Mortality risk06 Hizoh aimradial20170921 Mortality risk
06 Hizoh aimradial20170921 Mortality risk
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)
 
Testing Hypothesis
Testing HypothesisTesting Hypothesis
Testing Hypothesis
 
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...
Biostatistics Made Ridiculously Simple by Dr. Aryan (Medical Booklet Series b...
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
 
Dr Vivek Baliga - The Basics Of Medical Statistics
Dr Vivek Baliga - The Basics Of Medical StatisticsDr Vivek Baliga - The Basics Of Medical Statistics
Dr Vivek Baliga - The Basics Of Medical Statistics
 
Estimating risk
Estimating riskEstimating risk
Estimating risk
 
Biostatistics ii4june
Biostatistics ii4juneBiostatistics ii4june
Biostatistics ii4june
 
ODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATION
 
Stats chapter 12
Stats chapter 12Stats chapter 12
Stats chapter 12
 

Ähnlich wie Why to know statistics

RCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsRCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsDr. Majdi Al Jasim
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Isla Kuhn
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011NES
 
Understanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studyUnderstanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studykamolwantnok
 
2014 lab slides_mo_a
2014 lab slides_mo_a2014 lab slides_mo_a
2014 lab slides_mo_aA M
 
Statistics tests and Probablity
Statistics tests and ProbablityStatistics tests and Probablity
Statistics tests and ProbablityAbdul Wasay Baloch
 
Sesi 5 b ukuran dampak.2009l
Sesi 5 b ukuran dampak.2009lSesi 5 b ukuran dampak.2009l
Sesi 5 b ukuran dampak.2009lNANTRIW
 
Cohort study design.ppt Epidemiology medical
Cohort study design.ppt Epidemiology medicalCohort study design.ppt Epidemiology medical
Cohort study design.ppt Epidemiology medicalSoravSorout
 
MD Paediatricts (Part 2) - Epidemiology and Statistics
MD Paediatricts (Part 2) - Epidemiology and StatisticsMD Paediatricts (Part 2) - Epidemiology and Statistics
MD Paediatricts (Part 2) - Epidemiology and StatisticsBernard Deepal W. Jayamanne
 
Evidence-based diagnosis
Evidence-based diagnosisEvidence-based diagnosis
Evidence-based diagnosisHesham Gaber
 
Consider the following hypothet-ical scenario and results .docx
Consider the following hypothet-ical scenario and results .docxConsider the following hypothet-ical scenario and results .docx
Consider the following hypothet-ical scenario and results .docxdonnajames55
 
Bio statistical analysis in clinical research
Bio statistical analysis  in clinical research  Bio statistical analysis  in clinical research
Bio statistical analysis in clinical research Helwan University
 
Analytic StudiesThere are basically two types of studies experi.docx
Analytic StudiesThere are basically two types of studies experi.docxAnalytic StudiesThere are basically two types of studies experi.docx
Analytic StudiesThere are basically two types of studies experi.docxrossskuddershamus
 

Ähnlich wie Why to know statistics (20)

Risk assessment
Risk assessmentRisk assessment
Risk assessment
 
Displaying your results
Displaying your resultsDisplaying your results
Displaying your results
 
RCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsRCT Critical Appraisal - Results
RCT Critical Appraisal - Results
 
Statistics
StatisticsStatistics
Statistics
 
Risk Comparison
Risk ComparisonRisk Comparison
Risk Comparison
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
Understanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studyUnderstanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology study
 
2014 lab slides_mo_a
2014 lab slides_mo_a2014 lab slides_mo_a
2014 lab slides_mo_a
 
Statistics tests and Probablity
Statistics tests and ProbablityStatistics tests and Probablity
Statistics tests and Probablity
 
Sesi 5 b ukuran dampak.2009l
Sesi 5 b ukuran dampak.2009lSesi 5 b ukuran dampak.2009l
Sesi 5 b ukuran dampak.2009l
 
Cohort study design.ppt Epidemiology medical
Cohort study design.ppt Epidemiology medicalCohort study design.ppt Epidemiology medical
Cohort study design.ppt Epidemiology medical
 
MD Paediatricts (Part 2) - Epidemiology and Statistics
MD Paediatricts (Part 2) - Epidemiology and StatisticsMD Paediatricts (Part 2) - Epidemiology and Statistics
MD Paediatricts (Part 2) - Epidemiology and Statistics
 
Umeapresjr
UmeapresjrUmeapresjr
Umeapresjr
 
Evidence-Based Medicine Glossary
Evidence-Based Medicine GlossaryEvidence-Based Medicine Glossary
Evidence-Based Medicine Glossary
 
Evidence-based diagnosis
Evidence-based diagnosisEvidence-based diagnosis
Evidence-based diagnosis
 
Consider the following hypothet-ical scenario and results .docx
Consider the following hypothet-ical scenario and results .docxConsider the following hypothet-ical scenario and results .docx
Consider the following hypothet-ical scenario and results .docx
 
Can Personalized Medicine Save the Health Care System?
Can Personalized Medicine Save the Health Care System?Can Personalized Medicine Save the Health Care System?
Can Personalized Medicine Save the Health Care System?
 
Bio statistical analysis in clinical research
Bio statistical analysis  in clinical research  Bio statistical analysis  in clinical research
Bio statistical analysis in clinical research
 
Analytic StudiesThere are basically two types of studies experi.docx
Analytic StudiesThere are basically two types of studies experi.docxAnalytic StudiesThere are basically two types of studies experi.docx
Analytic StudiesThere are basically two types of studies experi.docx
 

Mehr von Hesham Al-Inany

Mehr von Hesham Al-Inany (20)

Updated HRT.pptx
Updated HRT.pptxUpdated HRT.pptx
Updated HRT.pptx
 
errors.pptx
errors.pptxerrors.pptx
errors.pptx
 
EndometriosisUpdate.pptx
EndometriosisUpdate.pptxEndometriosisUpdate.pptx
EndometriosisUpdate.pptx
 
DienogestMEFS.pptx
DienogestMEFS.pptxDienogestMEFS.pptx
DienogestMEFS.pptx
 
4G O.I.pptx
4G O.I.pptx4G O.I.pptx
4G O.I.pptx
 
miscarriage.pptx
miscarriage.pptxmiscarriage.pptx
miscarriage.pptx
 
OBGYNTech.pptx
OBGYNTech.pptxOBGYNTech.pptx
OBGYNTech.pptx
 
progesterone & Miscarriage.pptx
progesterone & Miscarriage.pptxprogesterone & Miscarriage.pptx
progesterone & Miscarriage.pptx
 
How to use technology to improve data integrity.pptx
How to use technology to improve data integrity.pptxHow to use technology to improve data integrity.pptx
How to use technology to improve data integrity.pptx
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
 
Updated hormone replacement therapy
Updated hormone replacement therapyUpdated hormone replacement therapy
Updated hormone replacement therapy
 
Fibroid & infertility
Fibroid & infertilityFibroid & infertility
Fibroid & infertility
 
Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor responders
 
Adenomyosis
AdenomyosisAdenomyosis
Adenomyosis
 
Ohss
OhssOhss
Ohss
 
Future of IVF : scoping view
Future of IVF : scoping viewFuture of IVF : scoping view
Future of IVF : scoping view
 
Ethics &amp; infertility
Ethics &amp; infertilityEthics &amp; infertility
Ethics &amp; infertility
 
Updates in endometrial receptivity
Updates in endometrial receptivityUpdates in endometrial receptivity
Updates in endometrial receptivity
 
Prp & reproduction
Prp & reproductionPrp & reproduction
Prp & reproduction
 
Pitfalls in management of infertility
Pitfalls in management of infertilityPitfalls in management of infertility
Pitfalls in management of infertility
 

Kürzlich hochgeladen

Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 

Kürzlich hochgeladen (20)

Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 

Why to know statistics

  • 1. Why to know statisticsWhy to know statistics
  • 2.  To understand dataTo understand data
  • 3. ExampleExample  One of your colleague is an oncologyOne of your colleague is an oncology surgeonsurgeon  60% of his cases died60% of his cases died  Does this mean that he is a looser!!Does this mean that he is a looser!!
  • 4.  We should ask what are the resultsWe should ask what are the results of his colleagues inof his colleagues in similarsimilar patientspatients  How many patients he operatedHow many patients he operated upon e.g 2/3!!!!upon e.g 2/3!!!!
  • 5.  To summarize dataTo summarize data
  • 6. ExampleExample  Diastolic Blood pressureDiastolic Blood pressure  80,70,65,90,74,80,60,90,60,75,80,980,70,65,90,74,80,60,90,60,75,80,9 0,100,100,100,950,100,100,100,95  AgeAge  24,30,26,40,28,21,26,31,32,36,27,424,30,26,40,28,21,26,31,32,36,27,4 5,62,58,52,50,605,62,58,52,50,60
  • 7. Vital for researchVital for research  Without the use of statistics it wouldWithout the use of statistics it would be very difficult to make decisionsbe very difficult to make decisions based on the data collected from abased on the data collected from a research projectresearch project
  • 8. Statistical steps in researchStatistical steps in research  Collect dataCollect data  Organise dataOrganise data  Analyse dataAnalyse data  Interpret the dataInterpret the data  Present the dataPresent the data
  • 9. How to read the resultsHow to read the results  An understanding of basic statisticsAn understanding of basic statistics will provide you with thewill provide you with the fundamental skills necessary to readfundamental skills necessary to read and evaluate results section inand evaluate results section in published paperspublished papers
  • 10. Are groups comparableAre groups comparable!!!!!!  the baseline characteristics of thethe baseline characteristics of the groups being studied should begroups being studied should be comparablecomparable  If not, they should be adjusted forIf not, they should be adjusted for differencesdifferences
  • 11. statistical testsstatistical tests  Are they frequently used tests!!Are they frequently used tests!!  If not, why!!If not, why!!
  • 12.  Are the data analysed accordingAre the data analysed according to the original protocol?to the original protocol?
  • 13.  Was follow- up complete?Was follow- up complete? Patients lost to follow-upPatients lost to follow-up………………loss ofloss of subjects biassubjects bias > 10% - 15 %> 10% - 15 % ……………………………………..invalid..invalid resultsresults
  • 14. P valueP value  A P value of <0.05 means that thisA P value of <0.05 means that this result would have arisen by chanceresult would have arisen by chance on less than one occasion in 20on less than one occasion in 20
  • 15. Standardization of measures of outcomeStandardization of measures of outcome:: Odds and odds ratioOdds and odds ratio The odds is the number of patients who fulfilThe odds is the number of patients who fulfil the criteria for a given endpoint divided bythe criteria for a given endpoint divided by the number of patients who do not.the number of patients who do not.
  • 16. For exampleFor example the odds of diarrhoea during treatment with anthe odds of diarrhoea during treatment with an antibiotic in a group of 10 patients may be 4antibiotic in a group of 10 patients may be 4 to 6 (4 with diarrhoea divided by 6 without,to 6 (4 with diarrhoea divided by 6 without, 0.66);0.66); in a control group the odds may be 1 to 9in a control group the odds may be 1 to 9 (0.11). The odds ratio of treatment to control(0.11). The odds ratio of treatment to control group would be 6 (0.66÷0.11).group would be 6 (0.66÷0.11).
  • 17. Risk and relative riskRisk and relative risk The risk is the number of patients whoThe risk is the number of patients who fulfil the criteria for a given end pointfulfil the criteria for a given end point divided by the total number of patients.divided by the total number of patients.
  • 18. For exampleFor example,, the risk of diarrhoea during treatmentthe risk of diarrhoea during treatment with an antibiotic in a group of 10with an antibiotic in a group of 10 patients may be 4 to 10; in the controlpatients may be 4 to 10; in the control group the risks may be 1 to 10. Thegroup the risks may be 1 to 10. The relative risk of treatment to controlrelative risk of treatment to control group would be 4 (0.4÷0.1).group would be 4 (0.4÷0.1).
  • 19. C.IC.I  The confidence interval around aThe confidence interval around a result in a clinical trial indicates theresult in a clinical trial indicates the limits within which the "real"limits within which the "real" difference between the treatments isdifference between the treatments is likely to lie,likely to lie,  hence the strength of the inferencehence the strength of the inference that can be drawn from the resultthat can be drawn from the result
  • 20. Example:Example: 95 %95 % CI for RRR 25 % :CI for RRR 25 % :  sample size 100sample size 100………………………….= -- 38 % to 59.= -- 38 % to 59 %%  Sample size 1000Sample size 1000…………………….= 9 % to 41 %.= 9 % to 41 % The larger the sample size , the narrower andThe larger the sample size , the narrower and more precise the CI , and the greater ourmore precise the CI , and the greater our confidence that the true RRR is closer toconfidence that the true RRR is closer to what we have observedwhat we have observed..
  • 21. OR = 0.34, 95% CI 0.23 - 0.52 • Odds Ratio < 1  decreased risk • Confidence Interval does not cross 1  statistically significant
  • 22.  A statistically significant result mayA statistically significant result may not be clinically significant.not be clinically significant.
  • 23.  The results of intervention trialsThe results of intervention trials should be expressed in terms of theshould be expressed in terms of the likely benefit an individual couldlikely benefit an individual could expect (for example, the absoluteexpect (for example, the absolute risk reduction)risk reduction)
  • 24. How large was the treatmentHow large was the treatment effecteffect?? Treatment effectTreatment effect………………………….. Adverse.. Adverse outcomeoutcome e.g.;e.g.; Risk of outcome without therapyRisk of outcome without therapy ( baseline risk )( baseline risk ) XX ( = 20 % or 0.20 )( = 20 % or 0.20 ) Risk of outcome with therapyRisk of outcome with therapy YY ( =( = 15% 0r 0.15)15% 0r 0.15)
  • 25.  Absolute risk reduction= X -- YAbsolute risk reduction= X -- Y 0.20-0.15= 0.050.20-0.15= 0.05  Relative risk ( RR )= Y / X = 0.15 /0.20 =Relative risk ( RR )= Y / X = 0.15 /0.20 = 0.750.75  Relative risk reduction ( RRR ) =Relative risk reduction ( RRR ) = { X -- Y/ X } x 100 % = 0.05 / 0.2 x{ X -- Y/ X } x 100 % = 0.05 / 0.2 x 100%= 25 % i.e :100%= 25 % i.e : therapy reduced the risk of the outcome by 25therapy reduced the risk of the outcome by 25 % relative to that occurring among the% relative to that occurring among the controlscontrols
  • 26. the greater the RRR, the morethe greater the RRR, the more effective the therapy.effective the therapy.
  • 27. Example: M.IExample: M.I  patients receiving medical treatmentpatients receiving medical treatment have a chance of 404/1324=0.305 orhave a chance of 404/1324=0.305 or 30.5% of being dead at 10 years.30.5% of being dead at 10 years.  Let us call this riskLet us call this risk xx. Patients. Patients randomised to coronary arteryrandomised to coronary artery bypass grafting have a chance ofbypass grafting have a chance of 350/1325=0.264 or 26.4% of being350/1325=0.264 or 26.4% of being dead at 10 years. Let us call this riskdead at 10 years. Let us call this risk yy..
  • 28. RRRR  The relative risk of deathThe relative risk of death——  that is, the risk in surgically treatedthat is, the risk in surgically treated patients compared with medicallypatients compared with medically treated controlstreated controls——isis  y/xy/x or 0.264/0.305=0.87 (87%).or 0.264/0.305=0.87 (87%).
  • 29. RRRRRR  The relative risk reductionThe relative risk reduction——that is,that is, the amount by which the risk ofthe amount by which the risk of death is reduced by the surgerydeath is reduced by the surgery——isis 100%-87% (1-100%-87% (1-yy//xx)=13%.)=13%.
  • 30. ARRARR  The absolute risk reduction (or riskThe absolute risk reduction (or risk difference)difference)——that is, the absolutethat is, the absolute amount by which surgical treatmentamount by which surgical treatment reduces the risk of death at 10 yearsreduces the risk of death at 10 years ——is 30.5%-26.4%=4.1% (0.041).is 30.5%-26.4%=4.1% (0.041).
  • 31. NNTNNT  The number needed to treatThe number needed to treat——howhow many patients need coronary arterymany patients need coronary artery bypass grafting in order to prevent,bypass grafting in order to prevent, on average, one death after 10 yearson average, one death after 10 years ——is the reciprocal of the absoluteis the reciprocal of the absolute risk reduction: 1/ARR=1/0.041=24.risk reduction: 1/ARR=1/0.041=24.
  • 32. ConclusionConclusion  to be able to effectively conductto be able to effectively conduct researchresearch  to be able to read and evaluateto be able to read and evaluate journal articlesjournal articles  to further develop critical thinkingto further develop critical thinking and analytic skillsand analytic skills  to know when you need to hireto know when you need to hire outside statistical helpoutside statistical help